疫苗前沿 | 治疗非小细胞肺癌，武田“first-in-class”精准疗法获FDA加速批准

参考资料：

[1] Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC. Retrieved September 15, 2021, from https://www.businesswire.com/news/home/20210915006101/en

[2] Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy. Retrieved January 28, 2021, from https://www.businesswire.com/news/home/20210128005072/en

来源：药明康德